ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).

[1]  J. Mendelsohn,et al.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma , 1993, Cancer Immunology, Immunotherapy.

[2]  C. Denkert,et al.  An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells , 2004, Clinical & Experimental Metastasis.

[3]  S. Salzano,et al.  The Cleavage of the Urokinase Receptor Regulates Its Multiple Functions* , 2002, The Journal of Biological Chemistry.

[4]  J. Brenton,et al.  Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. , 2002, Cancer research.

[5]  C. Der,et al.  Raf-independent Deregulation of p38 and JNK Mitogen-activated Protein Kinases Are Critical for Ras Transformation* , 2002, The Journal of Biological Chemistry.

[6]  L. Ossowski,et al.  EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. , 2002, Cancer cell.

[7]  Albert J. Fornace,et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.

[8]  Shuang Huang,et al.  Sequential Activation of the MEK-Extracellular Signal-Regulated Kinase and MKK3/6-p38 Mitogen-Activated Protein Kinase Pathways Mediates Oncogenic ras-Induced Premature Senescence , 2002, Molecular and Cellular Biology.

[9]  J. Aguirre Ghiso.  Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo , 2002, Oncogene.

[10]  K. Hahn,et al.  Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI. , 2002, Nature Reviews Molecular Cell Biology.

[11]  J. Kreidberg,et al.  Urokinase Receptors Promote β1 Integrin Function through Interactions with Integrin α3β1 , 2001 .

[12]  G. Naumov,et al.  Solitary cancer cells as a possible source of tumour dormancy? , 2001, Seminars in cancer biology.

[13]  W. Falk,et al.  A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. , 2001, Cancer research.

[14]  J. Westwick,et al.  Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. , 2001, Molecular cell.

[15]  S. Itoh,et al.  CHOP, a basic leucine zipper transcriptional factor, contributes to the antiproliferative effect of IL-1 on A375 human melanoma cells through augmenting transcription of IL-6. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  J. Aguirre-Ghiso,et al.  Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. , 2001, Molecular biology of the cell.

[17]  A. Hall,et al.  Rac Mediates Cytoskeletal Rearrangements and Increased Cell Motility Induced by Urokinase-Type Plasminogen Activator Receptor Binding to Vitronectin , 2001, The Journal of cell biology.

[18]  S. Pelech,et al.  Stress-induced Inhibition of ERK1 and ERK2 by Direct Interaction with p38 MAP Kinase* , 2001, The Journal of Biological Chemistry.

[19]  C. Kahn,et al.  Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. , 2001, Cancer research.

[20]  Jiahuai Han,et al.  The p38 Pathway Provides Negative Feedback for Ras Proliferative Signaling* , 2000, The Journal of Biological Chemistry.

[21]  U. Brinck,et al.  Comparative study of the expression of DNA mismatch repair genes, the adenomatous polyposis coli gene and growth arrest DNA damage genes in melanoma recurrences and metastases , 2000, Melanoma research.

[22]  D. Gillespie,et al.  Transient deactivation of ERK signalling is sufficient for stable entry into G0 in primary avian fibroblasts , 2000, Current Biology.

[23]  G. Naumov,et al.  Molecular biology of breast cancer metastasis: Clinical implications of experimental studies on metastatic inefficiency , 2000, Breast Cancer Research.

[24]  G. Nemerow,et al.  Urokinase Plasminogen Activator/Urokinase-specific Surface Receptor Expression and Matrix Invasion by Breast Cancer Cells Requires Constitutive p38α Mitogen-activated Protein Kinase Activity* , 2000, The Journal of Biological Chemistry.

[25]  S. Rosenberg,et al.  Identification of a Urokinase Receptor-Integrin Interaction Site , 2000, The Journal of Biological Chemistry.

[26]  Richard T. Lee,et al.  Direct Extracellular Contact between Integrin α3β1 and TM4SF Protein CD151* , 2000, The Journal of Biological Chemistry.

[27]  Jiahuai Han,et al.  Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. , 2000, Genes & development.

[28]  P. Roux,et al.  Differential Effect of Rac and Cdc42 on p38 Kinase Activity and Cell Cycle Progression of Nonadherent Primary Mouse Fibroblasts* , 2000, The Journal of Biological Chemistry.

[29]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[30]  U. Brinck,et al.  Loss of growth arrest DNA damage genes expression in oral melanomas. , 1999, In vivo.

[31]  L. Ossowski,et al.  Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling , 1999, The Journal of cell biology.

[32]  J. M. Lin,et al.  Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. , 1999, Cancer research.

[33]  G. Kapoor,et al.  One-way cross-talk between p38(MAPK) and p42/44(MAPK). Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/44(MAPK) cascade. , 1999, The Journal of biological chemistry.

[34]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[35]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[36]  S. Matsufuji,et al.  Antiproliferative effect of IL-1 is mediated by p38 mitogen-activated protein kinase in human melanoma cell A375. , 1999, Journal of immunology.

[37]  H. Ellinger-Ziegelbauer,et al.  Cell Cycle Arrest and Reversion of Ras-Induced Transformation by a Conditionally Activated Form of Mitogen-Activated Protein Kinase Kinase Kinase 3 , 1999, Molecular and Cellular Biology.

[38]  H. Chapman,et al.  A Role for Caveolin and the Urokinase Receptor in Integrin-mediated Adhesion and Signaling , 1999, The Journal of cell biology.

[39]  S. Zhuo,et al.  Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[40]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[41]  Jiahuai Han,et al.  Regulation of the MEF2 Family of Transcription Factors by p38 , 1999, Molecular and Cellular Biology.

[42]  Jiahuai Han,et al.  p38 Kinase is a negative regulator of angiotensin II signal transduction in vascular smooth muscle cells: effects on Na+/H+ exchange and ERK1/2. , 1998, Circulation research.

[43]  Erkki Ruoslahti,et al.  Fibronectin Matrix Regulates Activation of RHO and CDC42 GTPases and Cell Cycle Progression , 1998, The Journal of cell biology.

[44]  F. Cosset,et al.  In vivo selection of protease cleavage sites from retrovirus display libraries , 1998, Nature Biotechnology.

[45]  R. Yauch,et al.  Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. , 1998, Molecular biology of the cell.

[46]  D. Grignon,et al.  Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. , 1998, Cancer research.

[47]  R. Hynes,et al.  Novel Roles for α3β1 Integrin as a Regulator of Cytoskeletal Assembly and as a Trans-dominant Inhibitor of Integrin Receptor Function in Mouse Keratinocytes , 1998, The Journal of cell biology.

[48]  W. Yu,et al.  Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay , 1998, Cell.

[49]  E. Nishida,et al.  Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. , 1998, Science.

[50]  A. Schauer,et al.  Differential expression of growth arrest, DNA damage genes and tumour suppressor gene p53 in naevi and malignant melanomas. , 1997, Anticancer research.

[51]  E. Lengyel,et al.  Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade , 1997, Oncogene.

[52]  L. Zon,et al.  Cdc42Hs, but Not Rac1, Inhibits Serum-stimulated Cell Cycle Progression at G1/S through a Mechanism Requiring p38/RK* , 1997, The Journal of Biological Chemistry.

[53]  L. Ossowski,et al.  Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy , 1997, The Journal of cell biology.

[54]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[55]  E. Lengyel,et al.  Regulation of urokinase‐type plasminogen activator expression by an ERK1‐dependent signaling pathway in a squamous cell carcinoma cell line , 1996, Journal of cellular biochemistry.

[56]  Xiaozhong Wang,et al.  Stress-Induced Phosphorylation and Activation of the Transcription Factor CHOP (GADD153) by p38 MAP Kinase , 1996, Science.

[57]  E. Lengyel,et al.  Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras(*) , 1995, The Journal of Biological Chemistry.

[58]  C. Marshall,et al.  Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells , 1994, Cell.

[59]  A. Ashkenazi,et al.  Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. , 1993, The Journal of biological chemistry.

[60]  Robert Clarke,et al.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines , 1992, Journal of cellular physiology.

[61]  J. Trent,et al.  Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. , 1991, Cancer research.

[62]  L. Ossowski,et al.  Changes in malignant phenotype of a human carcinoma conditioned by growth environment , 1983, Cell.

[63]  S. Tokuoka,et al.  Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74. , 1979, Journal of the National Cancer Institute.